(PA20) Advantage in Application of Naturally Occurring Food Supplement in Oncological Patients

Title Advantage in Application of Naturally Occurring Food Supplement in Oncological Patients
Year 1996
Author L.Korkina; E. Samotchatova; M. Averbach; A. Moroz; J.A. Osato; I. Afanas;ev
Publisher Conference on Oxidative Stress and Redox Regulation: Cellular Signaling, AIDS, Cancer and other Diseases

In proceedings of the Oxidative Stress and Redox Regulation: Cellular Signaling, Aids, Cancer and Other Diseases

( Institut Pasteur, Paris, France, 21 – 24 May, 1996)


Advantages in Application of a Natural Occurring Food Supplement in Oncological Patients 

L. Korkina1, E.Samochatova1, M. Averbach1, A. Moroz1, J.A. Osato2, I. Afanas’evl

1Russian Institute of Pediatric Hematology, 117 Leninskii pr, Moscow 117513, Russia
2Sun-O International Inc., Gifu, Japan
3Vitamin Research Institute, 14 A Nauchny pr, Moscow 117840, Russia

Bio-Normalizer (BN), a completely natural nontoxic nutraceutical prepared by yeast fermentation of Carica papaya and other tropical herbs, possesses antioxidant, anti-inflamatory,

antifibrotic, and immunostimulatory activities. In the first part of this work, we investigated BN in the in vitro systems, to establish whether it is capable of affecting the tumor promoter PMA induced reactive oxygen species (ROS) production by human blood monocytes and neutrophils, and rat tissue macrophages, and the TNF-α production by blood monocytes. Another goal was to evaluate a direct anti-tumor effect of BN on tumor cells in cultures. We found that BN inhibited significantly the PMA-activated H2O2 and hydroxyl radical release from all kind of cells studied. On the other hand, BN increased superoxide, nitric oxide and TNF-α production by monocytes and macrophages. It has been shown also that BN itself exhibited a pronounced anti-tumor activity on lymphoma and sarcoma cell lines inducing their apoptotic death, and potentiated the anti-tumor effects of well-known anti-cancer agent vincristin.

On the grounds of the results obtained, we proposed the BN administration as a supportive care to patients with acute lympho- and myeloleukemias to prevent relapses and to decrease adverse effects of the conventional anti-tumor therapy. The randomized case-controlled open clinical trials have been performed. They have clearly shown that BN administration improved substantially the patients’ free radical status decreasing H2O2 and hydroxyl radical production by circulating leukocytes and lipid peroxidation in plasma, and enhancing the MnSOD expression and GSH content in the blood cells. Besides that, BN administration protected patients against both neurotoxic and hepatotoxic effects of chemo-and radiotherapies.


37

Advantages in application of a natural occurring food supplement in oncological patients

Korkina, L, Samochatova, E, Averbach, M, Moroz, A, Osato, A and Afanas’ev, I (presented at the conference on Oxidative Stress and Redox Regulation: Cellular Signaling, AIDS, Cancer and Other Diseases, Paris, France, 21-24 May 1996) ·

In this study, the effect of Bio-Normalizer on the production of reactive oxygen species by human monocytes and neutrophils and by rat tissue macrophages that have been stimulated with phorbol myristate acetate (PMA) was investigated. In addition, its effect of TNF-α production by monocytes was also examined. It was found that Bio-Normalizer significantly inhibited the PMA-activated release of hydrogen peroxide and hydroxyl radical from the cells. It also increased superoxide, nitric oxide and production of TNF-α by monocytes and macrophages.

Simultaneously, the anti-tumor activity of Bio-Normalizer was also evaluated in this experiment using lymphoma and sarcoma cell lines. It was observed that Bio-Normalizer induced apoptosis of the cancer cells. It also potentiated the anti-tumor effects of the well-known anti- cancer drug vincristin.

Based on the results, it is proposed that Bio-Normalizer be used as a supportive care to patients with acute lympho- and –myeloleukemias to prevent relapses and to decrease the adverse effects of the conventional anti-tumor therapy.